Mirati Therapeutics (MRTX) PT Raised to $225 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Mirati Therapeutics (MRTX) Prices 4.33M Share Common Offering at $202/Sh
October 28, 2020 5:57 AM EDTMirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $800.0 million, before... More
Mirati Therapeutics (MRTX) PT Raised to $210 at Piper Sandler
October 26, 2020 8:24 AM EDTPiper Sandler analyst Tyler Van Buren raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $210.00 (from $170.00) while maintaining an Overweight rating.
The analyst commented, "The adagrasib (formerly MRTX849) Phase Ib/II 45% ORR met investor expectations perour recent flash poll and appears improved versus... More
